January 2027 biotech catalysts

Name: Bio Catalyst Calendar — source-anchored biotech/pharma catalyst dates
Creator: Bio Catalyst Calendar
License: https://www.usa.gov/government-works

94 verified catalyst event(s) dated in January 2027, each linked to its official source. Verified as of 2026-11-04.

Date	Event	Company	Drug	Official source & verification
2027-01 (month) in 2mo ESTIMATED	READOUT A Phase 2b Clinical Study With a Combination Immunotherapy in Newly Diagnosed Pa Phase 2 · Glioblastoma	Imvax	IGV-001 Cell Immunotherapy, SOC: Temozol	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2027-01 (month) in 2mo ESTIMATED	READOUT Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies Phase 1/2 · Urinary Bladder Neoplasm, Triple Negative Breast Neoplasms	BicycleTx Limited	BT8009, Pembrolizumab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2027-01-01 in 2mo ESTIMATED	READOUT Study to Assess the Safety and Immunogenicity of TPOXX® When Administered Orally Phase 2 · Smallpox	SIGA SIGA TECHNOLOGIES INC	Tecovirimat, Smallpox and Mpox Vaccine	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2027-01 (month) in 2mo ESTIMATED	READOUT Safety, Pharmacokinetics, and Efficacy of AT 1501 in Patients Undergoing Kidney Phase 1/2 · Prevention of Rejection in Kidney Transplant	ELDN Eledon Pharmaceuticals, Inc.	AT-1501	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2027-01 (month) in 2mo ESTIMATED	READOUT A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixib Phase 2 · Primary Biliary Cholangitis, PBC	MIRM Mirum Pharmaceuticals, Inc.	Volixibat	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2027-01 (month) in 2mo ESTIMATED	READOUT A Study to Evaluate Efficacy and Safety of Light Dose in Subjects With PWB Treat Phase 2 · Port-wine Birthmarks, Port-Wine Stain	Shanghai Fudan-Zhangjiang Bio-Phar	Hemopfin+Green Light, Vehicle+Green Ligh	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2027-01 (month) in 2mo ESTIMATED	READOUT Safety Evaluation of Prismocitrate 18 in Patients Receiving CRRT Phase 3 · Regional Citrate Anticoagulation (RCA), Continuous Renal Replacement Therapy (CRRT)	Vantive Health LLC	Prismocitrate 18, PrisMax System Version	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2027-01 (month) in 2mo ESTIMATED	READOUT Assess Safety and Efficacy of VAD044 in HHT Patients Phase 1/2 · Hereditary Hemorrhagic Telangiectasia (HHT)	Vaderis Therapeutics AG	VAD044 Part I, VAD044 Part II	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2027-01 (month) in 2mo ESTIMATED	READOUT A Study of EDG-5506 in Children With Duchenne Muscular Dystrophy (LYNX) Phase 2 · Duchenne Muscular Dystrophy	EWTX Edgewise Therapeutics, Inc.	Sevasemten Dose 1, Sevasemten Dose 2, Se	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2027-01 (month) in 2mo ESTIMATED	READOUT A Clinical Study to Investigate the Efficacy of Intratumoral Tigilanol Tiglate i Phase 2 · Soft Tissue Sarcoma	QBiotics Group Limited	Tigilanol Tiglate	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2027-01 (month) in 2mo ESTIMATED	READOUT A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti Phase 1/2 · Advanced Solid Tumors	LigaChem Biosciences, Inc.	LCB84, Anti-PD-1 monoclonal antibody	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2027-01 (month) in 2mo ESTIMATED	READOUT Phase I/II Study of SKG0106 Intravitreal Injection in Patients With Neovascular Phase 1/2 · Neovascular Age-related Macular Degeneration	Skyline Therapeutics (US) Inc.	SKG0106	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2027-01 (month) in 2mo ESTIMATED	READOUT Study of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Act Phase 2 · Ulcerative Colitis	GILD GILEAD SCIENCES, INC.	Tilpisertib Fosmecarbil	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2027-01 (month) in 2mo ESTIMATED	READOUT A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Li Phase 2/3 · Hepatocellular Carcinoma	ABBV AbbVie Inc.	Livmoniplimab, Budigalimab, Durvalumab,	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2027-01 (month) in 2mo ESTIMATED	READOUT A Study Comparing Venetoclax and Azacitidine Plus Cusatuzumab to Venetoclax and Phase 2 · Leukemia, Myeloid, Acute	OncoVerity, Inc.	Cusatuzumab, Venetoclax, Azacitidine	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2027-01 (month) in 2mo ESTIMATED	READOUT JAB-30355 in Patients With Advanced Solid Tumors Harboring TP53 Y220C Mutation Phase 1/2 · Solid Tumors	Jacobio Pharmaceuticals Co., Ltd.	JAB-30355, JAB-30355	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2027-01 (month) in 2mo ESTIMATED	READOUT An Open-Label Study of CTI-1601 in Subjects With Friedreich's Ataxia Phase 2 · Friedreich Ataxia	LRMR Larimar Therapeutics, Inc.	CTI-1601	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2027-01 (month) in 2mo ESTIMATED	READOUT A Study to Evaluate the Efficacy and Safety of Sotagliflozin in Symptomatic Obst Phase 3 · Obstructive Cardiomyopathy, Hypertrophic, Non-obstructive Hypertrophic Cardiomyopathy	LXRX LEXICON PHARMACEUTICALS, INC	Sotagliflozin	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2027-01 (month) in 2mo ESTIMATED	READOUT Setrusumab in Pediatric Japanese Subjects With Osteogenesis Imperfecta Phase 3 · Osteogenesis Imperfecta	RARE Ultragenyx Pharmaceutical In	setrusumab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2027-01 (month) in 2mo ESTIMATED	READOUT A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Meropenem- Phase 2 · Acute Pyelonephritis, Complicated Urinary Tract Infection	Rempex (a wholly owned subsidiary	Meropenem-Vaborbactam, Antibiotics	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2027-01 (month) in 2mo ESTIMATED	READOUT Safety and Efficacy of Upadacitinib in Combination With Topical Corticosteroids Phase 3 · Atopic Dermatitis	ABBV AbbVie Inc.	Upadacitinib	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2027-01 (month) in 2mo ESTIMATED	READOUT A Study to Investigate the Safety, Tolerability, and Preliminary Efficacy With A Phase 1/2 · Chronic Kidney Disease Stage 3	AION Healthspan, Inc.	AION-301	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2027-01 (month) in 2mo ESTIMATED	READOUT A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors Phase 1/2 · Advanced Solid Tumors	CStone Pharmaceuticals	CS2009, CS2009, Pemetrexed, Carboplatin	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2027-01 (month) in 2mo ESTIMATED	READOUT "HB-adMSCs for the Treatment of Patients With Multiple Sclerosis" Phase 2 · Relapsing Remitting Multiple Sclerosis (RRMS), Multiple Sclerosis	Hope Biosciences Research Foundati	Autologous HB-adMSCs	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2027-01 (month) in 2mo ESTIMATED	READOUT A Study of Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-Targeti Phase 1/2 · Triple Negative Locally Advanced Non-resectable Breast Cancer, HR+, HER2-, Advanced Breast Cancer	Marengo Therapeutics, Inc.	STAR0602, Sacituzumab Govitecan (SG)	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2027-01 (month) in 2mo ESTIMATED	READOUT An Interventional Study of Infigratinib in Children With Hypochondroplasia Phase 2/3 · Hypochondroplasia	QED Therapeutics, a BridgeBio comp	infigratinib 0.128 mg/kg/day, infigratin	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2027-01 (month) in 2mo ESTIMATED	READOUT A Phase 1/2 Study to Evaluate the Safety, PK and Efficacy of TNP-2092 Administer Phase 1/2 · Periprosthetic Joint Infection (PJI)	TenNor Therapeutics Inc.	TNP-2092 for injection, Vancomycin Hydro	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2027-01 (month) in 2mo ESTIMATED	READOUT An Open-Label Study of Azetukalner in Major Depressive Disorder Phase 3 · Major Depressive Disorder	XENE Xenon Pharmaceuticals Inc.	Azetukalner	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2027-01 (month) in 2mo ESTIMATED	READOUT A Phase II, Placebo Controlled, Clinical Trial of Topical TolaSure Targeting Agg Phase 2 · Epidermolysis Bullosa Simplex	BioMendics, LLC	5% TolaSure Topical Gel, Topical Placebo	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2027-01 (month) in 2mo ESTIMATED	READOUT PSMA PET Combined With MRI for the Detection of PCa Phase 3 · PCA, Prostate Cancer	Telix Pharmaceuticals (Innovations	68Ga-PSMA-11	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2027-01 (month) in 2mo ESTIMATED	READOUT Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Face a Phase 3 · Actinic Keratosis	Sun Pharmaceutical Industries, Inc	Reformulated Levulan Kerastick containin	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2027-01 (month) in 2mo ESTIMATED	READOUT Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Upper Phase 3 · Actinic Keratosis	Sun Pharmaceutical Industries, Inc	Reformulated Levulan Kerastick containin	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2027-01 (month) in 2mo ESTIMATED	READOUT Study to Evaluate HM15275 in Obese or Overweight Subjects Without Diabetes Melli Phase 2 · Obese, Obesity	Hanmi Pharmaceutical Company Limit	HM15275	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2027-01 (month) in 2mo ESTIMATED	READOUT A Study of NTX-1472 in Social Anxiety Disorder Phase 2 · Social Anxiety Disorder (SAD)	Newleos Therapeutics, Inc.	NTX-1472	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2027-01 (month) in 2mo ESTIMATED	READOUT Randomized Clinical Trial Evaluating the Efficacy and Safety of Vormatrigine in Phase 3 · Focal Epilepsy	PRAX Praxis Precision Medicines,	40 mg/day vormatrogine for 12 weeks, 30	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2027-01 (month) in 2mo ESTIMATED	READOUT Phase 2a Dose Finding Study of Nu-3 Gel in Subjects With Mild iDFU Phase 2 · Diabetic Foot Ulcers (DFUs)	LABT Lakewood-Amedex Biotherapeut	Antimicrobial agent	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2027-01 (month) in 2mo ESTIMATED	READOUT An Investigation of FID 123472 Ophthalmic Solution to Vehicle for the Reduction Phase 3 · Ocular Hyperemia	Alcon Research	Apraclonidine Ophthalmic Solution, 0.125	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2027-01 (month) in 2mo ESTIMATED	READOUT A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Clinical Phase 2 · KCNT1-Related Epilepsy	Actio Biosciences, Inc.	ABS-1230	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2027-01 (month) in 2mo ESTIMATED	READOUT Clinical Evaluation of a Toothpaste for Dental Plaque Reduction and Prevention o Phase 3 · Plaque, Dental Plaque	CL COLGATE PALMOLIVE CO	0.45% SnF HW with NaF (1450 F), 67% Bica	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2027-01 (month) in 2mo ESTIMATED	READOUT An Open-Label, Safety and Efficacy Study of Cebranopadol in Participants With Ac Phase 3 · Pain	Adneuris Therapeutics, Inc.	Cebranopadol 400 ug	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2027-01-04 in 2mo ESTIMATED	READOUT Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-T Phase 3 · Arthritis, Psoriatic	MLTX MoonLake Immunotherapeutics	Sonelokimab, Risankizumab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2027-01-04 in 2mo ESTIMATED	READOUT A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With HeFH Phase 3 · Heterozygous Familial Hypercholesterolaemia	AZN ASTRAZENECA PLC	AZD0780	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2027-01-06 in 2mo ESTIMATED	READOUT Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY) Phase 3 · Systemic Sclerosis, Scleroderma	AZN ASTRAZENECA PLC	Anifrolumab (blinded), Anifrolumab (unbl	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2027-01-06 in 2mo ESTIMATED	READOUT A Study of AMG 732 in Healthy Participants and Participants With Thyroid Eye Dis Phase 1/2 · Thyroid Eye Disease	AMGN AMGEN INC	AMG 732	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2027-01-06 in 2mo ESTIMATED	READOUT A Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickl Phase 1/2 · Anemia, Sickle Cell, Healthy Volunteers	BMY BRISTOL MYERS SQUIBB CO	BMS-986470, Famotidine, Pantoprazole	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2027-01-06 in 2mo ESTIMATED	READOUT A Ph1b/2 Study of Axatilimab Monotherapy in Chinese Participants With Recurrent Phase 1/2 · Chronic Graft-versus-host-disease	INCY INCYTE CORP	INCA034176	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2027-01-07 in 2mo ESTIMATED	READOUT Study of a Single Dose of a 21-valent Pneumococcal Conjugate Vaccine in Children Phase 3 · Sickle Cell Disease	SNY Sanofi	PCV21, 20vPCV	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2027-01-08 in 2mo ESTIMATED	READOUT Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Impl Phase 3 · Neovascular Age-related Macular Degeneration	OCUL OCULAR THERAPEUTIX, INC	OTX-TKI, Aflibercept, Aflibercept	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2027-01-10 in 2mo ESTIMATED	READOUT A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Po Phase 3 · Relapsed or Refractory Multiple Myeloma	Celgene	mezigdomide, Pomalidomide, Bortezomib, D	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2027-01-11 in 2mo ESTIMATED	READOUT A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osime Phase 3 · Metastatic Non-small Cell Lung Cancer	AZN ASTRAZENECA PLC	Dato-DXd, Osimertinib, Pemetrexed, Carbo	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2027-01-11 in 2mo ESTIMATED	READOUT A Study of 2 Doses of Remigromig (EYE103) Compared With Ranibizumab (0.5 mg) in Phase 2/3 · Diabetic Macular Edema (DME)	EyeBiotech Ltd.	Remigromig, Ranibizumab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2027-01-11 in 2mo ESTIMATED	READOUT A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With Clin Phase 3 · Cardiovascular Disease	AZN ASTRAZENECA PLC	AZD0780	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2027-01-12 in 2mo ESTIMATED	READOUT Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Com Phase 3 · Carcinoma, Non-Small-Cell Lung	Merck Sharp & Dohme LLC	Sacituzumab Govitecan, Pembrolizumab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2027-01-12 in 2mo ESTIMATED	READOUT A Study Evaluating Persistence of the Immune Response of the Adjuvanted Respirat Phase 2 · Respiratory Syncytial Virus Infections	GlaxoSmithKline	Adjuvanted RSVPreF3 vaccine	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2027-01-13 in 2mo ESTIMATED	READOUT Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Phase 1/2 · Neovascular (Wet) AMD	Avirmax Biopharma Inc	ABI-110 Low Dose, ABI-110 Medium Dose, A	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2027-01-13 in 2mo ESTIMATED	READOUT A Study to Investigate Changes in Symptoms in Adult Participants With Chronic Rh Phase 3 · Chronic Rhinosinusitis With Nasal Polyps	AZN ASTRAZENECA PLC	Tezepelumab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2027-01-14 in 2mo ESTIMATED	READOUT A Research Study on How Well Different Doses of the Medicine UBT251 Help People Phase 2 · Overweight, Obesity	NVO NOVO NORDISK A S	UBT251	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2027-01-15 in 2mo ESTIMATED	READOUT Efficacy Against Oral Persistent Infection, Immunogenicity and Safety of the 9-v Phase 3 · Papillomavirus Infections	Merck Sharp & Dohme LLC	9vHPV Vaccine	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2027-01-15 in 2mo ESTIMATED	READOUT Long-term Safety and Efficacy of Efanesoctocog Alfa (BIVV001) in Previously Trea Phase 3 · Hemophilia A	Bioverativ, a Sanofi company	efanesoctocog alfa (BIVV001)	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2027-01-15 in 2mo ESTIMATED	READOUT IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Me Phase 2/3 · Metastatic Uveal Melanoma	IDYA IDEAYA Biosciences, Inc.	IDE196, Crizotinib, Pembrolizumab, Ipili	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2027-01-15 in 2mo ESTIMATED	READOUT A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HE Phase 2 · HER2-negative Breast Cancer Patients With Brain Metastases	Biostar Pharma, Inc.	Utidelone, Utidelone in combination with	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2027-01-16 in 2mo ESTIMATED	READOUT A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors Phase 1/2 · Solid Tumor, Adult	CRBP Corbus Pharmaceuticals Holdi	CRB-701, Anti-PD-1	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2027-01-18 in 3mo ESTIMATED	READOUT Study to Evaluate the Efficacy, Immunogenicity, and Safety of RSVpreF in Adults. Phase 3 · Lower Respiratory Tract Illness	PFE PFIZER INC	RSVpreF	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2027-01-18 in 3mo ESTIMATED	READOUT A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Antiviral Phase 3 · Cytomegalovirus (CMV)	TAK TAKEDA PHARMACEUTICAL CO LTD	Maribavir	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2027-01-18 in 3mo ESTIMATED	READOUT Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candid Phase 1/2 · Human Metapneumovirus Immunization, Respiratory Syncytial Virus Immunization	SNY Sanofi	Investigational hMPV/RSV vaccine, Invest	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2027-01-19 in 3mo ESTIMATED	READOUT A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of P Phase 3 · Non-Small Cell Lung Cancer	Hoffmann-La Roche	Alectinib, Entrectinib, Durvalumab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2027-01-19 in 3mo ESTIMATED	READOUT A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Phase 1/2 · Solid Tumor	SNY Sanofi	SAR445877, Cetuximab, ADG126, Bevacizuma	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2027-01-20 in 3mo ESTIMATED	READOUT Safety, Tolerability, and Effectiveness of Intramuscular Injection of CELZ-201-D Phase 1/2 · Chronic Low-back Pain, Degenerative Disc Disease	CELZ CREATIVE MEDICAL TECHNOLOGY	CELZ-201-DDT	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2027-01-20 in 3mo ESTIMATED	READOUT A Double-Blind, Randomized, Vehicle-Controlled Phase 2 Study to Assess the Effic Phase 2/3 · Eczema Atopic Dermatitis, Eczema	TTRX Turn Therapeutics Inc.	GX-03, Vehicle	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2027-01-21 in 3mo ESTIMATED	READOUT Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regim Phase 3 · Relapsing Multiple Sclerosis	TG Therapeutics, Inc.	Ublituximab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2027-01-21 in 3mo ESTIMATED	READOUT Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabe Phase 3 · Obesity	AMGN AMGEN INC	Maridebart Cafraglutide	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2027-01-21 in 3mo ESTIMATED	READOUT Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Phase 3 · Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight	AMGN AMGEN INC	Maridebart cafraglutide	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2027-01-25 in 3mo ESTIMATED	READOUT Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C M Phase 1/2 · KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small-Cell Lung	NVS NOVARTIS AG	JDQ443, TNO155, tislelizumab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2027-01-25 in 3mo ESTIMATED	READOUT Evaluation of the Long-term Safety and Effectiveness of Suzetrigine (SUZ) in Par Phase 3 · Diabetic Peripheral Neuropathic Pain	Vertex Pharmaceuticals Incorporate	Suzetrigine	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2027-01-25 in 3mo ESTIMATED	READOUT A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing Phase 3 · Diabetes Mellitus, Type 1	NVO NOVO NORDISK A S	Insulin icodec, Insulin glargine, Insuli	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2027-01-25 in 3mo ESTIMATED	READOUT A Phase 3 Study in India to Describe the Safety and Immunogenicity of RSVpreF Phase 3 · Respiratory Syncytial Virus (RSV)	PFE PFIZER INC	RSVpreF	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2027-01-26 in 3mo ESTIMATED	READOUT A Study to Investigate Faricimab Treatment Response in Treatment-Naive, Underrep Phase 4 · Diabetic Macular Edema	Genentech, Inc.	Faricimab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2027-01-26 in 3mo ESTIMATED	READOUT A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/V Phase 3 · Asthma	GlaxoSmithKline	FF/UMEC/VI, ELLIPTA, FF/VI	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2027-01-28 in 3mo ESTIMATED	READOUT A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy Adults Phase 3 · Influenza	ModernaTX, Inc.	mRNA-1018-H5	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2027-01-29 in 3mo ESTIMATED	READOUT Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRK Phase 1/2 · Metastatic Uveal Melanoma, Cutaneous Melanoma	IDYA IDEAYA Biosciences, Inc.	IDE196, Binimetinib, Crizotinib	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2027-01-29 in 3mo ESTIMATED	READOUT Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvest Phase 2 · Breast Neoplasms	NVS NOVARTIS AG	Alpelisib, Fulvestrant	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2027-01-29 in 3mo ESTIMATED	READOUT Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy. Phase 3 · C3G	NVS NOVARTIS AG	iptacopan	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2027-01-29 in 3mo ESTIMATED	READOUT Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Uro Phase 3 · Urothelial Carcinoma	Seagen, a wholly owned subsidiary	disitamab vedotin, pembrolizumab, gemcit	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2027-01-29 in 3mo ESTIMATED	READOUT ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo Phase 3 · Cardiovascular Risk, Acute Myocardial Infarction (AMI)	NVO NOVO NORDISK A S	Ziltivekimab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2027-01-29 in 3mo ESTIMATED	READOUT Immunogenicity, Safety, and Tolerability of rF1V-1018 Vaccine in Adults 18 to 55 Phase 2 · Prevention of Pneumonic Plague Resulting From Aerosol Exposure to Yersinia Pestis	Dynavax Technologies Corporation	rF1V-1018, rF1V-1018, rF1V-1018, rF1V-10	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2027-01-30 in 3mo ESTIMATED	READOUT Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer Phase 3 · Breast Cancer	Tolmar Inc.	TOL2506, Tamoxifen, Letrozole Tablets, A	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2027-01-30 in 3mo ESTIMATED	READOUT A Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121 Phase 3 · Moderately to Severely Active Ulcerative Colitis	Hoffmann-La Roche	Afimkibart	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2027-01-30 in 3mo ESTIMATED	READOUT Evaluation of Pain Treatment After Total Knee Arthroplasty Phase 4 · Pain	Vertex Pharmaceuticals Incorporate	Suzetrigine	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2027-01-31 in 3mo ESTIMATED	READOUT Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiothe Phase 3 · Urinary Bladder Neoplasms	Merck Sharp & Dohme LLC	Pembrolizumab, Conventional Radiotherapy	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2027-01-31 in 3mo ESTIMATED	READOUT Safety and Efficacy of CELZ-201 in Patients With Recent Onset Type 1 Diabetes Phase 1/2 · Type 1 Diabetes, Diabetes Mellitus, Type 1	CELZ CREATIVE MEDICAL TECHNOLOGY	CELZ-201 Administration, Control Group	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2027-01-31 in 3mo ESTIMATED	READOUT A Study of Combination Therapy With Amivantamab and Cetrelimab in Participants W Phase 1/2 · Carcinoma, Non-Small-Cell Lung	Janssen Research & Development, LL	Cetrelimab, Amivantamab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2027-01-31 in 3mo ESTIMATED	READOUT Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in Phase 2 · Relapsed or Refractory Aggressive B-Cell Non-Hodgkins Lymphoma	Hoffmann-La Roche	Obinutuzumab, Glofitamab, Gemcitabine, O	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2027-01-31 in 3mo ESTIMATED	READOUT Phase 2/3 Clinical Study of QRX003 Lotion in Subjects With Netherton Syndrome Phase 2/3 · Netherton Syndrome	QNRX Quoin Pharmaceuticals Ltd.	QRX003	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2027-01-31 in 3mo ESTIMATED	READOUT Abuse Potential of Gabapentin Taken Orally Concomitantly With Oxycodone Hydrochl Phase 4 · Healthy	VTRS Viatris Inc	Oxycodone 20mg, gabapentin 600 mg, Gabap	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change